Similarly, the levels of serum NSE and ProGRP were also higher in SCLC patients than those in BLD group and healthy control group (58.69 ± 13.35 ng/mL vs. 15.08 ± 2.43 ng/mL vs. 11.86 ± 0.77 ng/mL, p < 0.05; 726.95 ± 89.84 pg/mL vs. 72.33 ± 25.66 pg/mL vs. 41.43 ± 6.57 pg/mL, p < 0.05) (Figure 1B,C). This evidence concerns the gene ENO2 and small cell lung carcinoma.